Plain-English translation of NCT06292923 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called , given as a nasal spray, to see if it can slow down disability progression in people with secondary progressive multiple sclerosis (SPMS). SPMS is a stage of MS where symptoms gradually worsen over time. The study will compare two different doses of the medication against placebo (a non-active spray) over three months to see which works best.
Secondary progressive MS can continue to worsen even when people are taking standard MS treatments. This trial is exploring whether this new medication might help slow that progression by calming the immune system in a different way than current treatments do.
You would receive nasal sprays three days per week (Monday, Wednesday, Friday) for two weeks, then take one week off—and repeat this cycle four times over three months. Half the participants will receive one dose of the medication, a quarter will receive a higher dose, and a quarter will receive placebo, assigned randomly. You'll have study visits where doctors check your disability level, take brain images, and do blood tests to see how the treatment is working.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States